We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Sygnature Discovery Forms a Strategic Alliance with ApconiX
News

Sygnature Discovery Forms a Strategic Alliance with ApconiX

Sygnature Discovery Forms a Strategic Alliance with ApconiX
News

Sygnature Discovery Forms a Strategic Alliance with ApconiX

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Sygnature Discovery Forms a Strategic Alliance with ApconiX"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Sygnature Discovery has announced it is to work in partnership with ApconiX, experts in non-clinical safety strategies and ion channel screening, to offer a broader range of drug discovery services.

Dr Paul Clewlow, Senior VP, Business Development, recently signed the strategic alliance document with ApconiX which will allow them to add extra value and capabilities to Sygnature’s clients, specifically in the area of toxicology. The alliance will strengthen Sygnature’s integrated drug discovery service offering to accelerate the discovery of new medicines from the lab into development for clients.

ApconiX is a team of world-renowned non-clinical safety experts with over 300 years of drug discovery and development expertise. They provide advice that helps scientists to make better decisions on drug safety, from project initiation through to worldwide marketing approval, guiding you towards scientific and regulatory success.

Based in the BioHub at Alderley Park, Cheshire – part of the BioCity Group where Sygnature Discovery is headquartered – ApconiX delivers high quality, cost-effective pre-clinical safety packages that align with drug discovery projects.

Dr Clewlow of Sygnature Discovery commented:
“Toxicology and functional electrophysiology assessments are essential aspects of the drug discovery and development process to ensure the safety of a potential drug prior to administration in humans. The specialists at ApconiX are world renowned scientists in non-clinical safety strategies and their skills will be of great benefit to our clients. The alliance between Sygnature Discovery and ApconiX will be mutually beneficial and together we can offer a more comprehensive integrated approach to any clients’ drug discovery programme.

We are very much looking forward to working with ApconiX and introducing them to our clients.”

Dr Michael Morton, Director and Co-Founder of ApconiX, commented:
“The combination of our expertise in discovery toxicology and ion channel testing, with that of Sygnature’s medicinal chemistry-driven integrated drug discovery services, will help clients to make safer drugs. Our ability to run high-throughput screens for important ion channel targets also compliments Sygnature’s extensive biology capability. This is a hugely exciting partnership!”
Advertisement